<?xml version="1.0" encoding="UTF-8"?>
<p id="par0040">IFN-I were first discovered more than 60 years ago as antiviral substances produced by influenza virus-infected cells, capable of markedly inhibiting viral replication in target cells [
 <xref rid="bib0045" ref-type="bibr">9</xref>]. These cytokines were the firsts to be cloned and have been extensively used in patients with some viral diseases [
 <xref rid="bib0050" ref-type="bibr">10</xref>] and cancer (IFN-α) [
 <xref rid="bib0055" ref-type="bibr">11</xref>], and in the treatment of relapsing-remitting multiple sclerosis (MS) (IFN-β, [
 <xref rid="bib0060" ref-type="bibr">12</xref>]). Indeed, IFN-I are pleiotropic factors endowed with multiple activities, including both a broad-spectrum antiviral activity [
 <xref rid="bib0045" ref-type="bibr">9</xref>,
 <xref rid="bib0050" ref-type="bibr">10</xref>] and a remarkable antiproliferative and immunoregulatory function [
 <xref rid="bib0065" ref-type="bibr">13</xref>].
</p>
